Three things to know from the latest Patient Experience Survey
Most insured Americans believe insurance should provide affordable access to health care (93%), but only a third (34%) say it does, according to thefourth installment of the Patient Experience Survey (PES). The survey — based on interviews with 5,000 Americans — explores this disconnect, detailing the challenges insured Americans face affording care and how practices by health insurers and middlemen put patient lifelines to access at risk. (Source: The Catalyst)
Source: The Catalyst - July 20, 2023 Category: Pharmaceuticals Authors: Cynthia Hicks Tags: Health Insurance Out-of-Pocket Costs Pharmacy Benefit Managers Polling Source Type: news
Key considerations as Congress works towards PAHPA reauthorization
This week, PhRMAsubmitted comments to the U.S. Senate Committee on Health, Education, Labor and Pensions (HELP) regarding the Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization draft. In our comments, we expressed our strong opposition to policy proposals that would inhibit the biopharmaceutical industry partnering with the government to address pressing public health needs. With many PAHPA programs set to expire on September 30th and only a few legislative days left before the start of August work period, it is critical that lawmakers of both parties work together to ensure timely reauthorization of core pr...
Source: The Catalyst - July 12, 2023 Category: Pharmaceuticals Authors: Jocelyn Ulrich Tags: Research and Development Drug Cost Coronavirus Antimicrobial Resistance Source Type: news
New studies add to body of evidence questioning 340B efficacy
Recent studies add to the growing body of evidence questioning the value of the current 340B program and whether it ’s benefiting patients as Congress intended. (Source: The Catalyst)
Source: The Catalyst - July 11, 2023 Category: Pharmaceuticals Tags: 340B Source Type: news
Between hope and despair: Improving cancer outcomes
I can still see everything in the hospital room in my mind ’s eye, the night — 13 days before Christmas — a neurologist delivered the news to my mother and me that she had non-Hodgkin’s lymphoma, an aggressive tumor lodged in her brain. It threw our little family into a panic and into a search for the best treatment available in the subsequent 8 mon ths before her death. Unfortunately, the tumor was diagnosed late in progression and inoperable. In 2009, there weren’t many treatment options available, and the doctors weren’t sure how to respond because not many Black patients had had similar diagnoses, so there ...
Source: The Catalyst - July 11, 2023 Category: Pharmaceuticals Authors: Courtney Christian Tags: Cancer Health Equity Source Type: news
New report shows high-impact R & D happens after cancer medicines are first approved
A new report showcasing nine critical oncology treatments, highlights the vital role of post-approval research and development (R&D) in advancing cancer treatment options and deliveringunprecedented progress in the fight against cancer over the past 10 years. (Source: The Catalyst)
Source: The Catalyst - July 10, 2023 Category: Pharmaceuticals Authors: Lindsey Seidlitz Tags: Research and Development PhRMA Member Company Cancer Government Price Setting Source Type: news
A conversation with Dr. Mike Ybarra on the current state of COVID-19
On May 11th of this year, the COVID-19 national public health emergency (PHE) officially ended, marking an incredible milestone in the fight against COVID-19. While the end of the PHE signals a new chapter in the fight against COVID-19, the biopharmaceutical industry ’s work continues to ensure our health care system is well-prepared for any curve balls this virus might throw as well as staying ahead of the next pandemic. (Source: The Catalyst)
Source: The Catalyst - June 27, 2023 Category: Pharmaceuticals Authors: Matthew Norawong Tags: Vaccines Coronavirus Antimicrobial Resistance Source Type: news
More than 60 researchers ask Congress to support innovation
Earlier this month, 62 researchers from our member companies came to Washington, DC to meet with congressional offices during our annual fly-in event. This year included a record-breaking number of meetings — 145 over the course of the day. (Source: The Catalyst)
Source: The Catalyst - June 26, 2023 Category: Pharmaceuticals Tags: PhRMA Member Company Policy Solutions Government Price Setting Source Type: news
New report shows how the Inflation Reduction Act stifles innovation for small molecule medicines
Research doesn ’t endonce a medicine is first approved by the U.S. Food and Drug Administration (FDA). Researchers often spend years after an initial approval exploring and obtaining approval of new indications for medicines to treat other patient populations desperate for new treatment options. Patients with cancer or rare diseases often depend on this post-approval research. (Source: The Catalyst)
Source: The Catalyst - June 22, 2023 Category: Pharmaceuticals Tags: Research and Development Rare Diseases Cancer Government Price Setting Source Type: news
How FDA ’s modernization strategy could improve drug development
As technology continues to rapidly advance, it ’s important for regulatory agencies like the U.S. Food and Drug Administration (FDA) to keep pace and adopt new technologies and approaches to support its public health mission and ultimately, better serve patients. (Source: The Catalyst)
Source: The Catalyst - June 20, 2023 Category: Pharmaceuticals Authors: Rebecca Nebel, PhD Tags: PDUFA Digital Health Source Type: news
Biopharmaceutical science powered by PRIDE
This June marks Lesbian, Gay, Bisexual, Transgender and Queer (LGBTQ+) Pride Month. At PhRMA, we ’re proud to celebrate the diversity and inclusion of our LGBTQ+ colleagues and the patients our companies aim to help. As an industry driven by science, we believe diversity in the lab drives greater collaboration, scientific advancement and groundbreaking medicines impacting the lives of patient s. (Source: The Catalyst)
Source: The Catalyst - June 16, 2023 Category: Pharmaceuticals Tags: Research and Development Equity Source Type: news
New data: America is an API powerhouse
Policymakers and the media have been taking a close look at the medicalsupply chain recently, including the manufacturing locations of active pharmaceutical ingredients (APIs) for medicines used by Americans. APIs are what make a medicine a medicine — they are the substance in the medicine that treats or cures a disease or affects a condition within the body. During the manufacturing process, chemical or biological materials are synthesized or grown and then purified into APIs. APIs are then combined with other materials to create a finished drug product. (Source: The Catalyst)
Source: The Catalyst - June 16, 2023 Category: Pharmaceuticals Authors: Megan Van Etten Tags: Manufacturing Source Type: news
Reject efforts to undermine America ’s R & D ecosystem
America ’s biopharmaceutical research companies are central to the research and development (R&D) of innovative medicines in the United States. Unfortunately, a new report by Sen. Sanders mischaracterizes the role the National Institutes of Health plays in the research and development (R&D) process and risks stifling the innovative biopharmaceutical ecosystem vital to advancing medicines for patients. (Source: The Catalyst)
Source: The Catalyst - June 15, 2023 Category: Pharmaceuticals Tags: Research and Development Intellectual Property Source Type: news
ASCO 2023: Protecting our progress in the fight against cancer
I always look forward to the American Society of Clinical Oncology ’s Annual Meeting, which took place in Chicago earlier this month. It’s an opportunity for the world’s leading cancer experts to celebrate the latest innovations that are changing the treatment paradigm for patients with this disease. (Source: The Catalyst)
Source: The Catalyst - June 15, 2023 Category: Pharmaceuticals Tags: Research and Development Cancer Government Price Setting Source Type: news
340B program reaches $100 billion in sales, while patients are left behind
The 340B Drug Pricing Program has grownyet again, exceeding$100 billion in sales in 2022 when 340B-priced medicines are measured at wholesale acquisition cost. Recentdata from IQVIA shows 340B grew 12.2% year-over-year in 2022, continuing a trend in which 340B sales have almost doubled since 2018, outpacing growth of the total U.S. drug market. (Source: The Catalyst)
Source: The Catalyst - June 14, 2023 Category: Pharmaceuticals Tags: 340B Source Type: news
Highlights from ASCO 2023
Last week, I traveled to the American Society of Clinical Oncology ’s (ASCO) annual meeting. It’s always an exceptional meeting where the brightest minds in oncology, including researchers, health care providers and industry stakeholders gather to learn about the latest advancements in cancer research and development (R&D). (Source: The Catalyst)
Source: The Catalyst - June 8, 2023 Category: Pharmaceuticals Authors: Michael Ybarra Tags: Research and Development Cancer Government Price Setting Source Type: news
